EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Epigenetic profiling of prostate cancer reveals potential prognostic signatures

Simon Bernatz, Ian G Reddin, Tim R Fenton, Thomas J Vogl, Peter J Wild, Jens Köllermann, Philipp Mandel, Mike Wenzel, Benedikt Hoeh, Scherwin Mahmoudi, Vitali Koch, Leon D Grünewald and 4 more

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05921-0 ↗

At a glance

Journal article in Journal of Cancer Research and Clinical Oncology, 2024. Written by Simon Bernatz and 15 co-authors. Institution: Goethe University Frankfurt, University Hospital, Clinic for Radiology and Nuclear Medicine, Frankfurt am Main, Germany. Major MEDLINE topics: Prostatic Neoplasms, Epigenesis, Genetic, DNA Methylation, Biomarkers, Tumor. Cited 3 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY 4.0). Funded by: Johann Wolfgang Goethe-Universität, Frankfurt am Main.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Purpose

While epigenetic profiling discovered biomarkers in several tumor entities, its application in prostate cancer is still limited. We explored DNA methylation-based deconvolution of benign and malignant prostate tissue for biomarker discovery and the potential of radiomics as a non-invasive surrogate.

Methods

We retrospectively included 30 patients (63 [58–79] years) with prostate cancer (PCa) who had a multiparametric MRI of the prostate before radical prostatectomy between 2014 and 2019. The control group comprised four patients with benign prostate tissue adjacent to the PCa lesions and four patients with benign prostatic hyperplasia. Tissue punches of all lesions were obtained. DNA methylation analysis and reference-free in silico deconvolution were conducted to retrieve Latent Methylation Components (LCMs). LCM-based clustering was analyzed for cellular composition and correlated with clinical disease parameters. Additionally, PCa and adjacent benign lesions were analyzed using radiomics to predict the epigenetic signatures non-invasively.

Results

LCMs identified two clusters with potential prognostic impact. Cluster one was associated with malignant prostate tissue ( p < 0.001) and reduced immune-cell-related signatures ( p = 0.004) of CD19 and CD4 cells. Cluster one comprised exclusively malignant prostate tissue enriched for significant prostate cancer and advanced tumor stages ( p < 0.03 for both). No radiomics model could non-invasively predict the epigenetic clusters.

Conclusion

Epigenetic clusters were associated with prognostically and clinically relevant metrics in prostate cancer. Further, immune cell-related signatures differed significantly between prognostically favorable and unfavorable clusters. Further research is necessary to explore potential diagnostic and therapeutic implications.

Subjects

MeSH terms (MEDLINE)

Prostatic NeoplasmsEpigenesis, GeneticDNA MethylationBiomarkers, TumorHumansMaleAgedPrognosisMiddle AgedRetrospective StudiesProstatectomy

Author keywords

DNA methylation-based tumor deconvolutionProstate cancerRadiomics

Substances

Biomarkers, Tumor

Authors and institutions

  • Goethe University Frankfurt, University Hospital, Clinic for Radiology and Nuclear Medicine, Frankfurt am Main, Germany.
  • Goethe University Frankfurt, University Hospital, Dr. Senckenberg Institute for Pathology, Frankfurt am Main, Germany.
  • Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.
  • School of Cancer Sciences, University of Southampton, Southampton, UK.
  • Frankfurt Institute for Advanced Studies (FIAS), Frankfurt am Main, Germany.
  • Goethe University Frankfurt, University Hospital, Department of Urology, Frankfurt am Main, Germany.

Funding

  • Johann Wolfgang Goethe-Universität, Frankfurt am Main

Cite

APA

Bernatz, S., Reddin, I. G., Fenton, T. R., Vogl, T. J., Wild, P. J., Köllermann, J., Mandel, P., Wenzel, M., Hoeh, B., Mahmoudi, S., Koch, V., Grünewald, L. D., Hammerstingl, R., Döring, C., Harter, P. N., & Weber, K. J. (2024). Epigenetic profiling of prostate cancer reveals potential prognostic signatures. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05921-0

Vancouver

Bernatz S, Reddin IG, Fenton TR, Vogl TJ, Wild PJ, Köllermann J, et al. Epigenetic profiling of prostate cancer reveals potential prognostic signatures. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05921-0

BibTeX
@article{Bernatz2024,
  author = {Bernatz, Simon and Reddin, Ian G and Fenton, Tim R and Vogl, Thomas J and Wild, Peter J and Köllermann, Jens and Mandel, Philipp and Wenzel, Mike and Hoeh, Benedikt and Mahmoudi, Scherwin and Koch, Vitali and Grünewald, Leon D and Hammerstingl, Renate and Döring, Claudia and Harter, Patrick N and Weber, Katharina J},
  title = {Epigenetic profiling of prostate cancer reveals potential prognostic signatures},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05921-0}
}
Start for free →